Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.40 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.40 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.40 |
| ▸ | HSPA2 | P54652 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143963 | 1.00 | EPHX1 (0.44) | EPHX1PDPK1CYP1A2SLC6A2TAAR1 | |
| SCHEMBL6685124 | 1.00 | EPHX1 (0.44) | EPHX1PDPK1CYP1A2SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL22691669 | 0.98 | EPHX1 (0.42) | EPHX1PDPK1CYP1A2SLC6A2TAAR1 | |
| Hydrochloric Acid SCHEMBL22691671 | 0.98 | EPHX1 (0.42) | EPHX1PDPK1CYP1A2SLC6A2TAAR1 | |
| SCHEMBL2808151 | 0.91 | PDPK1 (0.46) | PDPK1TAAR1HSPA1AHSPA5HSPA9 | |
| Trifluoroacetic Acid SCHEMBL28342750 | 0.89 | PTPRB (0.43) | PKMHSPA1AHSPA5HSPA9HSPA2 | |
| SCHEMBL792960 | 0.87 | LTA4H (0.53) | CYP1A2SLC6A2MAOASLC6A3CTSA | |
| Hydrochloric Acid SCHEMBL772237 | 0.86 | LTA4H (0.52) | CYP1A2SLC6A2MAOASLC6A3CTSA | |
| SCHEMBL19257973 | 0.85 | RAD52 (0.46) | SLC6A4PTPRB | |
| Hydrochloric Acid SCHEMBL20586638 | 0.83 | RAD52 (0.45) | MAOASLC6A4PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4426714-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118541378-A | Novel auristatin analogues and immunoconjugates thereof | 艾德森特克斯治疗股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2023-05-30 | — | — | US | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-6103698-A | USEFUL IN TREATING CANCER IN A MAMMAL; IN COMBINATION WITH PACLITAXEL AND TAXOTERE | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-15 | — | — | US | disclosed |
| EP-0981358-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | disclosed |
| US-6020495-A | Stereoselective method for synthesizing dolaphenine | PHARM-ECO LABORATORIES, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6015790-A | Methods and compositions for treating rheumatoid arthritis | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-18 | — | — | US | disclosed |
| WO-1998040092-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| EP-0642530-B1 | DERIVATIVES OF DOLASTATIN | BASF AG (DE) | 1998-08-12 | — | — | EP | disclosed |
| US-5750713-A | Stereoselective method for synthesizing dolaphenine | PHARM-ECO LABORATORIES, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1996039399-A1 | STEREOSELECTIVE METHOD FOR SYNTHESIZING DOLAPHENINE | PHARM-ECO LABORATORIES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| EP-0642530-A1 | DERIVATIVES OF DOLASTATIN | BASF Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
| WO-1993023424-A1 | DERIVATIVES OF DOLASTATIN | BASF AKTIENGESELLSCHAFT (DE) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | EPHX1 1895/4885PDPK1 4580/4885CYP1A2 2433/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | EPHX1 3108/4885PDPK1 3505/4885CYP1A2 2554/4885 |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | EPHX1 4663/4885PDPK1 1398/4885CYP1A2 3703/4885 |
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | FCGR2A, FCGR3B, AURKC | EPHX1 4227/4885PDPK1 3950/4885CYP1A2 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.